Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL RADIONUCLIDE INJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL RADIONUCLIDE INJECTION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL RADIONUCLIDE INJECTION MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PIPELINE ANALYSIS
6. PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 PORTER’S 5 FORCES
6.3 GLOBAL RADIONUCLIDE INJECTION MARKET ANALYSIS
7. INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8. REGULATORY FRAMEWORK
9. GLOBAL RADIONUCLIDE INJECTION MARKET , BY USE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 ABSCESS AND INFECTION
9.2.1.1. GALLIUM CITRATE GA 67
9.2.1.2. INDIUM IN 111 OXYQUINOLINE
9.2.1.3. OTHERS
9.2.2 BLOOD VESSEL DISEASES
9.2.2.1. SODIUM PERTECHNETATE TC 99M
9.2.2.2. AMMONIA N 13
9.2.2.3. IOFETAMINE I 123
9.2.2.4. BICISATE
9.2.2.5. EXAMETAZIME
9.2.2.6. XENON XE 133
9.2.2.7. OTHERS
9.2.3 BRAIN DISEASES
9.2.3.1. FLUDEOXYGLUCOSE F 18
9.2.3.2. INDIUM IN 111 PENTETREOTIDE
9.2.3.3. IOFETAMINE I 123
9.2.3.4. SODIUM PERTECHNETATE
9.2.3.5. OTHERS
9.2.4 CANCER
9.2.4.1. FLUDEOXYGLUCOSE F 18
9.2.4.2. GALLIUM CITRATE GA 67
9.2.4.3. INDIUM IN 111 PENTETREOTIDE
9.2.4.4. METHIONINE C 11
9.2.4.5. RADIOIODINATED IOBENGUANE
9.2.4.6. SODIUM FLUORIDE F 18
9.2.4.7. TECHNETIUM TC 99M
9.2.4.8. OTHERS
9.2.5 HEART DISEASE
9.2.5.1. AMMONIA N 13
9.2.5.2. FLUDEOXYGLUCOSE F 18
9.2.5.3. RUBIDIUM RB 82
9.2.5.4. TECHNETIUM TC 99M
9.2.5.5. OTHERS
9.2.6 KIDNEY DISEASES
9.2.6.1. IODOHIPPURATE SODIUM
9.2.6.2. TECHNETIUM TC 99M
9.2.6.3. OTHER
9.2.7 LIVER DISEASES
9.2.7.1. AMMONIA N 13
9.2.7.2. FLUDEOXYGLUCOSE F 18
9.2.7.3. TECHNETIUM TC 99
9.2.8 LUNG DISEASES
9.2.8.1. KRYPTON KR 81M
9.2.8.2. TECHNETIUM TC 99
9.2.8.3. XENON XE
9.2.9 OTHERS
9.3 THERAPEUTIC NUCLEAR MEDICINE
9.3.1 BRACHYTHERAPY
9.3.1.1. BY TYPE
9.3.1.1.1. LOW-DOSE RATE (LDR)
9.3.1.1.2. HIGH-DOSE RATE (HDR)
9.3.1.1.3. PERMANENT
9.3.1.2. BY RADIOACTIVE MATERIAL
9.3.1.2.1. IODINE-131
9.3.1.2.2. IRIDIUM-192
9.3.1.2.3. IODINE-125
9.3.1.2.4. PALLADIUM-103
9.3.1.2.5. OTHERS
9.3.2 ANTIBODY THERAPY
9.3.2.1. BY TYPE
9.3.2.1.1. ANTIBODY CONJUGATED RADIOIMMUNOTHERAPY
9.3.2.1.1.1 CONVENTIONAL SINGLE-STEP
9.3.2.1.1.2 MULTI-STEP PRETARGETED
9.3.2.1.2. OTHERS RADIOIMMUNOTHERAPY
9.3.2.2. BY RADIOPHARMACUETICAL
9.3.2.2.1. YTTRIUM-90 IBRITUMOMAB TIUXETAN
9.3.2.2.2. IODINE-131
9.3.2.2.3. OTHERS
9.3.3 TARGETED ALPHA THERAPY (TAT)
9.3.3.1. ACTINIUM-225
9.3.3.2. THORIUM-232
9.3.3.3. OTHERS
10. GLOBAL RADIONUCLIDE INJECTION MARKET , BY PARTICLE
10.1 OVERVIEW
10.2 CAESIUM-131
10.3 PALLADIUM-103
10.4 RADIUM-223
10.5 ACTINIUM-225
10.6 LEAD-212
10.7 TECHNETIUM TC 99
10.8 THORIUM-227
10.9 ASTATINE-211
10.10 IODINE-131
10.11 IRIDIUM-192
10.12 IODINE-125
10.13 PALLADIUM-103
10.14 OTHERS
11. GLOBAL RADIONUCLIDE INJECTION MARKET , BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12. GLOBAL RADIONUCLIDE INJECTION MARKET , BY AGE GROUP
12.1 OVERVIEW
12.2 CHILD
12.3 ADULT
12.4 GERIATRIC
13. GLOBAL RADIONUCLIDE INJECTION MARKET , BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.2.1 BY TYPE
13.2.1.1. PUBLIC
13.2.1.2. PRIVATE
13.2.2 BY USE
13.2.2.1. DIAGNOSTIC
13.2.2.2. THERAPEUTICS
13.3 CANCER CARE CENTERS
13.3.1 DIAGNOSTIC
13.3.2 THERAPEUTICS
13.4 RESEARCH AND ACADEMIC INSTITUES
13.4.1 DIAGNOSTIC
13.4.2 THERAPEUTICS
13.5 OTHERS
14. GLOBAL RADIONUCLIDE INJECTION MARKET , BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT SALES
14.3 INDIRECT SALES
15. GLOBAL RADIONUCLIDE INJECTION MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16. GLOBAL RADIONUCLIDE INJECTION MARKET, BY GEOGRAPHY
GLOBAL RADIONUCLIDE INJECTION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 FRANCE
16.2.3 U.K.
16.2.4 POLAND
16.2.5 ITALY
16.2.6 SPAIN
16.2.7 RUSSIA
16.2.8 TURKEY
16.2.9 NETHERLANDS
16.2.10 SWITZERLAND
16.2.11 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 JAPAN
16.3.2 CHINA
16.3.3 SOUTH KOREA
16.3.4 INDIA
16.3.5 AUSTRALIA
16.3.6 SINGAPORE
16.3.7 THAILAND
16.3.8 MALAYSIA
16.3.9 INDONESIA
16.3.10 PHILIPPINES
16.3.11 VIETNAM
16.3.12 REST OF ASIA-PACIFIC
16.4 SOUTH AMERICA
16.4.1 BRAZIL
16.4.2 ARGENTINA
16.4.3 REST OF SOUTH AMERICA
16.5 MIDDLE EAST AND AFRICA
16.5.1 SOUTH AFRICA
16.5.2 SAUDI ARABIA
16.5.3 UAE
16.5.4 EGYPT
16.5.5 KUWAIT
16.5.6 ISRAEL
16.5.7 REST OF MIDDLE EAST AND AFRICA
16.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17. GLOBAL RADIONUCLIDE INJECTION MARKET, SWOT AND DBMR ANALYSIS
18. GLOBAL RADIONUCLIDE INJECTION MARKET , COMPANY PROFILE
18.1 ADVANCED ACCELERATOR APPLICATIONS USA, INC.
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 BLUE EARTH DIAGNOSTICS
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPEMENTS
18.3 BRACCO DIAGNOSTICS INC.
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 CARDINAL HEALTH, INC.
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 CURIUM US LLC
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 JUBILANT DRAXIMAGE INC.
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 ECKERT & ZIEGLER RADIOPHARMA INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 GE HEALTHCARE, INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 ION BEAM APPLICATIONS S.A.
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.10 LANTHEUS MEDICAL IMAGING, INC.
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 MEDI-RADIOPHARMA LTD.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 MEDICAL ISOTOPES, INC.
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 NORDION (CANADA) INC.
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPEMENTS
18.15 ONCOVISION, INC.
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPEMENTS
18.16 PHILIPS HEALTHCARE
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPEMENTS
18.17 RADIOMEDIX, INC.
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPEMENTS
18.18 SIEMENS MEDICAL SOLUTIONS USA, INC.
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 SPECTRUM DYNAMICS MEDICAL, INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.20 TELIX PHARMACEUTICALS LIMITED
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 SOFIE
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 CURIUM
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19. CONCLUSION
20. QUESTIONNAIRE
21. ABOUT DATA BRIDGE MARKET RESEARCH
